Login to Your Account



Rigontec gets $12M for RNA-based immunotherapies

By Cormac Sheridan
Staff Writer

Tuesday, October 14, 2014
Rigontec GmbH, a spinout from the University of Bonn in Germany, took in €9.45 million (US$12 million) in a first closing of a series A round to take forward an RNA-based approach to immunotherapy, based on activating retinoic acid inducible protein I (RIG-I), a pathogen-associated molecular pattern that recognizes certain forms of viral RNA.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription